Ken-Ichiro Kato Selected Research

Ken-Ichiro Kato Research Topics

8	Type 2 Diabetes Mellitus (MODY) 02/2022 - 01/2012
3	Insulin Resistance 03/2015 - 01/2012
2	Body Weight (Weight, Body) 02/2022 - 01/2015
2	Non-alcoholic Fatty Liver Disease 03/2015 - 01/2012
1	Overweight 05/2019
1	Liver Diseases (Liver Disease) 01/2018
1	Diabetic Nephropathies (Diabetic Nephropathy) 05/2015
1	Proteinuria 05/2015
1	Hyperglycemia 03/2015
1	Fibrosis (Cirrhosis) 01/2012
1	Inflammation (Inflammations) 01/2012
1	Duodenal Neoplasms (Duodenal Cancer) 01/2012
1	Neoplasms (Cancer) 01/2012
1	Neoplasm Metastasis (Metastasis) 01/2012
1	Adenocarcinoma 01/2012

5	Glucose (Dextrose)FDA LinkGeneric 02/2022 - 01/2012
4	Sitagliptin Phosphate (Januvia)FDA Link 01/2018 - 01/2015
3	Metformin (Glucophage)FDA LinkGeneric 02/2022 - 01/2012
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 02/2022 - 01/2018
2	Short-Acting InsulinIBA 01/2018 - 01/2015
1	SodiumIBA 02/2022
1	SymportersIBA 02/2022
1	dapagliflozinIBA 02/2022
1	alogliptinIBA 05/2019
1	Insulin Detemir (Levemir)FDA Link 01/2018
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2018
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2018
1	Insulin Aspart (NovoLog)FDA Link 01/2018
1	voglibose (Basen)IBA 01/2016
1	Hemoglobins (Hemoglobin)IBA 01/2016
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2016
1	CreatinineIBA 05/2015
1	Atorvastatin (Lipitor)FDA Link 05/2015
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2015
1	Pravastatin (Pravachol)FDA LinkGeneric 05/2015
1	Liraglutide FDA Link 03/2015
1	VildagliptinIBA 03/2015
1	Insulin (Novolin)FDA Link 01/2015
1	mitiglinideIBA 01/2015
1	somatostatin receptor 2IBA 01/2012
1	Triglycerides (Triacylglycerol)IBA 01/2012
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2012
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2012
1	SynaptophysinIBA 01/2012
1	ChromograninsIBA 01/2012
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2012
1	Cisplatin (Platino)FDA LinkGeneric 01/2012
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2012